CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 220 enrolled
Drug / intervention
Oxygendrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03020212
NCT03020212N/ACompleted

Long-term Oxygen Therapy in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Live at High Altitude (2640 Meters Above Sea Level): Evaluation of a Proposal for Adjusting Criteria

Fundación Neumologica Colombiana·interventional·Posted Jan 13, 2017·Updated Mar 14, 2025

In Brief

A clinical study evaluating Oxygen for COPD. Completed, enrolled 220 participants across 1 site.

Detailed Summary

A clinical, prospective, randomized controlled trial to determine the effect of prescribing oxygen in a group of COPD (chronic pulmonary disease) patients with PaO2 (arterial oxygen tension) ≥50 and ≤55 mmHg who do not have erythrocytosis or pulmonary hypertension on echocardiogram (which are considered manifestations of chronic hypoxia)

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOPD
CountriesColombia

Timeline

N/ACompletedFinished
20162017201820192020202120222023202420252026
First PostedJan 13, 2017
Enrollment StartFeb 1, 2016
Primary CompletionJan 1, 2025
TodayJul 2, 2026
Enrollment to primary: 8.9 yearsPosted 9.5 years ago

Interventions

Oxygendrug

The subjects will be randomly assigned to receive or not LTOT and they will be followed for 30 months. At baseline and then at 10, 20 and 30 months, they will be clinically evaluated with arterial blood gases, pulse oximetry, echocardiography, spirometry with bronchodilator, diffusion capacity, quality of life (SGRQ), neurocognitive performance (MMSE) and six minutes walk test. The primary outcome will evaluate the ratio of occurrence of erythrocytosis or pulmonary hypertension. Secondary outcomes will be evaluated quality of life, lung function, neurocognitive performance and exercise tolerance by comparing the groups with and without LTOT.